Alvotech: Why FDA Delays Don't Break The Bull Case
Source: SeekingAlpha
2026-01-21 21:34:46 ET
Since my October article , "My 5 Biggest Biotech Stocks Big Pharma Can Buy Now", Alvotech stock ( ALVO ) has fallen 44%, underperforming the S&P 500 [2.2% return] ( SPY )....
Read the full article on Seeking Alpha
For further details see:
Alvotech: Why FDA Delays Don't Break The Bull Case
Organon & Co.
NASDAQ: OGN
OGN Trading
-2.03% G/L:
$6.285 Last:
1,322,256 Volume:
$6.41 Open:
OGN Latest News
February 27, 2026 08:00:00 am
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
February 23, 2026 07:30:00 am
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine Device
OGN Stock Data
$2,031,766,457
254,887,247
0.05%
304
N/A
Pharmaceuticals
Healthcare
US
Jersey City
